1-5 of 5
Sahar Ansari
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Circulating Tumor DNA (ctDNA) As an Early Outcome Predictor in Patients (pts) with Second-Line (2L) Large B-Cell Lymphoma (LBCL) after Lisocabtagene Maraleucel (liso-cel) Versus Standard of Care (SOC) Treatment (tx) from the Phase 3, Randomized Transform Study

Lara Stepan, Sahar Ansari, Abood Okal, Justine Dell'Aringa, Ethan G. Thompson, Alessandro Crotta, Victor A. Chow, Jeremy S. Abramson, Manali Kamdar, Scott R. Solomon, Patrick B. Johnston, Bertram Glass, Pim Mutsaers, Jon E. Arnason, Stephan Mielke, Mazyar Shadman, Francisco Hernandez-Ilizaliturri, Koji Izutsu, Veronika Bachanova, Sami Ibrahimi, Jacob Chabon, David Kurtz, Ash A. Alizadeh, Leanne Peiser
Journal: Blood
Blood (2024) 144 (Supplement 1): 72.
https://doi.org/10.1182/blood-2024-199813
Published: 2024
Journal Articles

Undetectable MRD Status in Patients with R/R CLL/SLL with Stable Disease after Lisocabtagene Maraleucel Treatment: Exploratory Analysis of the TRANSCEND CLL 004 Study

Eniko Papp, Sahar Ansari, Jason Wall, Ethan Thompson, Yizhe Chen, Tanya Siddiqi, William G. Wierda, Serena K. Perna, Sherilyn A. Tuazon, Abood Okal, Leanne Peiser
Journal: Blood
Blood (2023) 142 (Supplement 1): 3263.
https://doi.org/10.1182/blood-2023-180230
Published: 2023
Journal Articles

Circulating Tumor DNA Dynamics as Early Outcome Predictors for Lisocabtagene Maraleucel as Second-Line Therapy for Large B-Cell Lymphoma from the Phase 3 TRANSFORM Study

Lara Stepan, Sahar Ansari, Abood Okal, Justine Dell'Aringa, Ethan Thompson, Alessandro Crotta, Victor A Chow, Jeremy S. Abramson, Manali Kamdar, Jacob J. Chabon, Gregory Hogan, David M. Kurtz, Ash A. Alizadeh, Leanne Peiser
Journal: Blood
Blood (2023) 142 (Supplement 1): 225.
https://doi.org/10.1182/blood-2023-181007
Published: 2023
Journal Articles

Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results

Clinical Trials & Observations
Ranjana H. Advani, Alison J. Moskowitz, Nancy L. Bartlett, Julie M. Vose, Radhakrishnan Ramchandren, Tatyana A. Feldman, Ann S. LaCasce, Beth A. Christian, Stephen M. Ansell, Craig H. Moskowitz, Lisa Brown, Chiyu Zhang, David Taft, Sahar Ansari, Mariana Sacchi, Linda Ho, Alex F. Herrera
Journal: Blood
Blood (2021) 138 (6): 427–438.
https://doi.org/10.1182/blood.2020009178
Published: 2021
Includes: Supplemental data
Journal Articles

Brentuximab Vedotin and Nivolumab for Relapsed or Refractory Classic Hodgkin Lymphoma: Long-Term Follow-up Results from the Single-Arm Phase 1/2 Study

Alison J. Moskowitz, MD, Ranjana H Advani, MD, Nancy L. Bartlett, MD, Julie M Vose, MDMBA, Radhakrishnan Ramchandren, MD, Tatyana A. Feldman, MD, Ann S. LaCasce, MD MMSc, Beth A. Christian, MD, Stephen M Ansell, MD PhD, Craig H. Moskowitz, Lisa Brown, David Taft, Sahar Ansari, Daniel E. Zak, PhD, Mariana Sacchi, MD, Thomas Manley, MD, Alex F. Herrera, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 238.
https://doi.org/10.1182/blood-2019-122576
Published: 2019